RADX News

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases

AtomVie Global Radiopharma fournit la première dose à un patient dans le cadre de l'étude clinique de phase 1/2a de Radiopharm Theranostics sur le 177Lu-BetaBart (RV-01) USA - Français USA - Deutsch USA - English

AtomVie Global Radiopharma liefert erste Patientendosis in Phase 1/2a der klinischen Studie von Radiopharm Theranostics mit 177Lu-BetaBart (RV-01) USA - Deutsch USA - English USA - Français

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) USA - English USA - Français USA - Deutsch USA - English APAC - English